Publication | Closed Access

Rivaroxaban improves survival and decompensation in cirrhotic patients with moderate liver dysfunction. Double-blind, placebo-controlled trial

Moderate Liver DysfunctionHepatologyGastrointestinal PharmacologyLiver PhysiologyRivaroxaban Improves SurvivalGastroenterologyHepatology InflammationPlacebo-controlled TrialPharmacotherapyHepatotoxicityLiver DiseaseHepatology FibrosisLiverMedicineDrug-induced Liver Injury